DOCSLIB.ORG

Elite Pgx Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Elite Pgx Report Comprehensive PGx report for SANDRA HENRY PERSONAL DETAILS Redwood Lab Services LLC CLIA:45D2108203 Fax: PATIENT ENRY DOB 281-378-2116 281-466-2483 Address: 6776 Southwest Fwy Suite 600, Houston, TX 77074 GENDER Female Website: http://www.redwoodlabservices.com/ SPECIMEN TYPE Buccal Swab LABORATORY INFORMATION ORDERING PHYSICIAN - ACCESSION NUMBER 2006271582 FACILITY Elite Clinical Lab COLLECTION DATE 06/03/2020 RECEIVED DATE 07/01/2020 REPORT GENERATED 09/21/2020 LABORATORY DIRECTOR Chad Harper Current Patient Medication This patient is either not receiving any medication or may be receiving medications that are outside the scope of this report. A medication has potentially reduced ecacy, increased toxicity or the patient has a risk for the indicated condition. Guidelines exist for adjusting dosage, increased vigilance or the patient has risk for the indicated condition. The medication can be prescribed according to standard regimens or the patient's risk for the indicated condition is not increased. Comprehensive PGx report for SANDRA HENRY 1 / 29 G E NOTYP E /HAP L OTYP E /P HE NOTYP E DE TAIL Dis claimer: No patient should evaluate or use the information contained herein without the advice, consultation and supervision of a licensed healthcare professional such as a pharmacist or G ene G enotype-Haplotype P henotype physician. Laboratory-developed testing characteristics and protocols. R esults have not been reviewed or approved by the U.S . Food & Drug Administration (FDA). * This call was defaulted to the wild-type allele frequency because during review of the genotyping data, the genotype was C YP 1A2 *1A/*1A E xtensive metabolizer indeterminate. For copy number: ** This copy number was defaulted to the wild-type frequency because during review of the copy number variation data, the copy number was indeterminate. C YP 2B6 *1/*1 E xtensive metabolizer C YP 2C 8 *1/*1 E xtensive metabolizer Methodology: Array based assays detect listed alleles, including all common and most rare C YP 2C 9 *1/*1 E xtensive metabolizer variants with known clinical significance at analytical sensitivity and specificity >99%. C YP 2C 19 *1/*1 E xtensive metabolizer L imitations : Testing cannot detect all genetic mutations, inactive or altered genes. The absence of C YP 2D6 *1/*39 E xtensive metabolizer a finding of a detectable gene, polymorphism or mutation does not necessarily indicate patient C YP 3A4 *1/*1 E xtensive metabolizer possesses intermediate or high sensitivity phenotypes or that patient has an undetected polymorphism. Absence of finding may be due to drug-drug interaction. C YP 3A5 *3/*3 P oor metabolizer C YP 4F2 *1/*1 E xtensive metabolizer P HAR MAC OG E NOMIC S VK OR C 1 *1/*1 Warfarin res is tance S LC O1B1 *1/*1 E xtensive function G enetic Markers Tested for P harmacogenomics: TP MT *1/*1 E xtensive metabolizer R esults are arranged by drug response. E ach individual report contains six sections, including: UG T1A1 *1/*1 E xtensive metabolizer P atient’s current medication (if any), Medication history, genotype/haplotype/phenotype detail, P G x DP YD *1/*1 E xtensive metabolizer report, G enomic Test R esults, and P atient Information C ard. Inclusion of the P G x R eport indicates that the tested individual: displays decreased ecacy to the drug (yellow check marks), should use OP R M1 *1/*1 S ensitive to Opioids the drug as directed (green check marks), or exhibits increased toxicity to the drug (red check marks). Inclusion of G enomic Test R esults indicates genotype, haplotype, phenotype, or presence of mutation. Organization of Table: 1. G ene/Locus refers to gene or intergenic region of genetic marker location. 2. Marker refers to the tested marker’s unique identifier. 3. G enotype/Haplotype refers to the particular marker’s combination of nucleotides. The letter(s) on either side of the slash refer(s) to the two (2) copies of the patient DNA. Del and dashes denotes nucleotide indels in patient DNA. E mpty cells indicate an absence of genotyping results. 4. P henotype refers to the C YP specific drug metabolizing capabilities of an individual. S ee R IS KS AND LIMITATIONS on the last pages of this R eport. C omprehens ive P G x report for S ANDR A HE NR Y 2 / 29 P G x R eport - P ain Management Type: Anti-inflammatory Agent, Analgesic, Antipyretic May Have May Have Used As Drug C lass G eneric P rimary Mechanism Involved Other Mechanisms Involved Decreased Increased Directed E fficacy Toxicity The Nonsteroidal Antiinflammatory Drugs (NS AIDs) Nabumetone (R elafen) C YP 1A2 C YP 2C 19, C YP 3A4 Acetic acid derivatives Indomethacin (Tivorbex) C YP 2C 9 C YP 2C 19 Ketorolac (Toradol, Acular, C YP 2C 8 C YP 2C 9, UG T2B7 S prix) Meloxicam (Mobic, Vivlodex) C YP 2C 9 C YP 1A2, C YP 3A4, C YP 3A5 E nolic acid (Oxicam) P iroxicam (Feldene) C YP 2C 9 C YP 3A4, C YP 3A5 derivatives Tenoxicam (Mobiflex) C YP 2C 9 Lornoxicam (FLE XILOR ) C YP 2C 9 E toricoxib (Arcoxia) C YP 3A4 C YP 3A5, C YP 2C 9, C YP 2D6, C YP 1A2 S elective C OX-2 inhibitors P arecoxib (Dynastat) C YP 2C 9 C YP 3A4, C YP 3A5 (C oxibs) C elecoxib (C elebrex) C YP 2C 9 C YP 2C 19 Ibuprofen (Motrin, Advil) C YP 2C 9 C YP 2C 19, C YP 2C 8 Flurbiprofen (Ocufen) C YP 2C 9 Ketoprofen (Frotek) C YP 3A4 C YP 2C 9, C YP 3A5 Fenoprofen (Nalfon, P ropionic acid derivatives C YP 2C 9 Fenortho) Vicoprofen (R eprexain, C YP 2D6 C YP 3A4 Ibudone) Naproxen (Aleve, Naprosyn) C YP 2C 9 C YP 1A2, C YP 2C 8 Anthranilic acid derivatives Mefenamic acid (P onstel) C YP 2C 9 (Fenamates) UG T1A1, UG T1A6, UG T1A9, The Non-NS AIDs Analgesic Acetaminophen (Tylenol) C YP 3A4, C YP 3A5, C YP 2D6, C YP 1A2 S ULT1A1, G S Hs P G x R eport - P ain Management Type: Opioid May Have May Have Used As Drug C lass G eneric P rimary Mechanism Involved Other Mechanisms Involved Decreased Increased Directed E fficacy Toxicity Opioid Analgesics C YP 3A4, UG T2B4, FMO3, C YP 3A5, Opium alkaloids C odeine C YP 2D6 OP R M1 E sters of morphine Diacetylmorphine (Heroin) C E S 1 C E S 2, OP R M1 Dihydrocodeine (DHC P lus, C YP 3A4 C YP 2D6, C YP 3A5 E thers of morphine P anlor) E thylmorphine (C odethyline) C YP 2D6 C YP 3A4, C YP 3A5 Hydrocodone (Hysingla, C YP 2D6 C YP 3A4, C YP 3A5, OP R M1 S emi-synthetic alkaloid Vicodin) derivatives Oxycodone (Oxycontin, C YP 3A4 C YP 3A5, C YP 2D6, C OMT R oxicodone) S ynthetic opioids Alfentanyl C YP 3A4 C YP 3A5, OP R M1 Fentanyl (Duragesic, Anilidopiperidine derivatives C YP 3A4 C YP 3A5, OP R M1 S ubsys) S ufentanil (S ufenta) C YP 3A4 C YP 3A5, OP R M1 Meperidine (Demerol) C YP 2B6 C YP 3A4, C YP 2C 19, C YP 3A5 P henylpiperidine derivatives Ketobemidone (Ketogan) C YP 2C 9 C YP 3A4, C YP 3A5 Dextropropoxyphene C YP 3A4 C YP 3A5, R enal E xcretion (Darvon) Levacetylmethadol (Orlaam) C YP 3A4 C YP 3A5 Diphenylpropylamine Loperamide (Anti-diarrhea, derivatives C YP 3A4 C YP 2C 8, C YP 3A5 Diamode) Methadone (Methadose, C YP 3A4 C YP 2B6, C YP 2D6, C YP 3A5, C OMT Diskets) Buprenorphine (Buprenex, Oripavine derivatives C YP 3A4 C YP 3A5, C YP 2C 8, UG T1A1 Butrans) Dextromethorphan Morphinan derivatives C YP 2D6 C YP 3A4, C YP 3A5 (R obitussin, Dayquil) C YP 3A4, C YP 2B6, C YP 3A5, OP R M1, Tramadol C YP 2D6 C OMT Tapentadol (Nucynta, Others C YP 2C 9 C YP 2C 19, C YP 2D6 Nucynta E R ) Tilidine (Valoron) C YP 3A4 C YP 2C 19, C YP 3A5 Anti-opioid Methylnaltrexone (R elistor) C YP 2D6 C YP 3A4, C YP 3A5 C omprehens ive P G x report for S ANDR A HE NR Y 3 / 29 P G x R eport - P ain Management Type: Drugs P rescribed for the Treatment of G out, Antirheumatic May Have May Have Used As Drug C lass G eneric P rimary Mechanism Involved Other Mechanisms Involved Decreased Increased Directed E fficacy Toxicity Drugs P rescribed for G out Uricosurics S ulfinpyrazone (Anturane) C YP 2C 9 C YP 3A4, C YP 3A5 Mitotic inhibitors C olchicine (C olcrys, Mitigare) C YP 3A4 C YP 3A5 Febuxostat (Uloric) C YP 1A2, C YP 2C 8 C YP 2C 9, UG T1A1 Allopurinol (Zyloprim, Xanthine oxidase inhibitors AOX1 R enal E xcretion, HLA-B*5801 Aloprim) Oxypurinol R enal E xcretion R ecombinant urate oxidase R asburicase (E litek) C YB5R 1, C YB5R 2, C YB5R 3, C YB5R 4 DMAR Ds Leflunomide (Arava) C YP 1A2 Tofacitinib (Xeljanz, Anti-inflammatory C YP 3A4 C YP 2C 19, C YP 3A5 J akvinus) Abbreviations: DMAR Ds, Disease-modifying antirheumatic drugs; R E , renal excretion (unchanged drug). Additional S NP s of Importance for P ain Management Level of G ene Marker G enotype Drug R esults E vidence OP R M1 rs1799971 A/A Naloxone (Narcan, E vzio) 2B P atients may have lower cortisol response Morphine (Duramorph, P ain patients may experience increased efficacy of opioids and may be less susceptible to opioid addiction, OP R M1 rs1799971 A/A 2B Infumorph P /F) and may require a decreased dose of opioids P ain patients may experience increased efficacy of opioids and may be less susceptible to opioid addiction, OP R M1 rs1799971 A/A Alfentanil 2B and may require a decreased dose of opioids Fentanyl (Duragesic, P ain patients may experience increased efficacy of opioids and may be less susceptible to opioid addiction, OP R M1 rs1799971 A/A 2B S ubsys) and may require a decreased dose of opioids P ain patients may experience increased efficacy of opioids and may be less susceptible to opioid addiction, OP R M1 rs1799971 A/A Tramadol 2B and may require a decreased dose of opioids Hydrocodone (Hysingla, P atients may have a decreased risk for experiencing side effects, including constipation, dry mouth or OP R M1 rs1799971 A/A 3 Vicodin) respiratory depression C OMT rs4680 * P aroxetine (P axil, S eroxat)
Load more

Recommended publications
  • New Developments in Prokinetic Therapy for Gastric Motility Disorders
    REVIEW published: 24 August 2021 doi: 10.3389/fphar.2021.711500 New Developments in Prokinetic Therapy for Gastric Motility Disorders Michael Camilleri* and Jessica Atieh Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States Prokinetic agents amplify and coordinate the gastrointestinal muscular contractions to facilitate the transit of intra-luminal content. Following the institution of dietary recommendations, prokinetics are the first medications whose goal is to improve gastric emptying and relieve symptoms of gastroparesis. The recommended use of metoclopramide, the only currently approved medication for gastroparesis in the United States, is for a duration of less than 3 months, due to the risk of reversible or irreversible extrapyramidal tremors. Domperidone, a dopamine D2 receptor antagonist, is available for prescription through the FDA’s program for Expanded Access to Investigational Drugs. Macrolides are used off label and are associated with tachyphylaxis and variable duration of efficacy. Aprepitant relieves some symptoms of gastroparesis. There are newer agents in the pipeline targeting diverse gastric (fundic, antral and pyloric) motor functions, including novel serotonergic 5-HT4 agonists, dopaminergic D2/3 antagonists, neurokinin NK1 antagonists, and ghrelin agonist. Novel Edited by: targets with potential to improve gastric motor functions include the pylorus, macrophage/ Jan Tack, inflammatory function, oxidative
    [Show full text]
  • Therapeutic Class Overview Irritable Bowel Syndrome Agents
    Therapeutic Class Overview Irritable Bowel Syndrome Agents Therapeutic Class Overview/Summary: This review will focus on agents used for the treatment of Irritable Bowel Syndrome (IBS).1-5 IBS is a gastrointestinal syndrome characterized primarily by non-specific chronic abdominal pain, usually described as a cramp-like sensation, and abnormal bowel habits, either constipation or diarrhea, in which there is no organic cause. Other common gastrointestinal symptoms may include gastroesophageal reflux, dysphagia, early satiety, intermittent dyspepsia and nausea. Patients may also experience a wide range of non-gastrointestinal symptoms. Some notable examples include sexual dysfunction, dysmenorrhea, dyspareunia, increased urinary frequency/urgency and fibromyalgia-like symptoms.6 IBS is defined by one of four subtypes. IBS with constipation (IBS-C) is the presence of hard or lumpy stools with ≥25% of bowel movements and loose or watery stools with <25% of bowel movements. When IBS is associated with diarrhea (IBS-D) loose or watery stools are present with ≥25% of bowel movements and hard or lumpy stools are present with <25% of bowel movements. Mixed IBS (IBS-M) is defined as the presence of hard or lumpy stools with ≥25% and loose or water stools with ≥25% of bowel movements. Final subtype, or unsubtyped, is all other cases of IBS that do not fall into the other classes. Pharmacological therapy for IBS depends on subtype.7 While several over-the-counter or off-label prescription agents are used for the treatment of IBS, there are currently only two agents approved by the Food and Drug Administration (FDA) for the treatment of IBS-C and three agents approved by the FDA for IBS-D.
    [Show full text]
  • Prophylactic Antiemetic Therapy with Ondansetron, Granisetron and Metoclopramide in Patients Undergoing Laparoscopic Cholecystectomy Under GA
    JK SCIENCE ORIGINAL ARTICLE Prophylactic Antiemetic Therapy with Ondansetron, Granisetron and Metoclopramide in Patients Undergoing Laparoscopic Cholecystectomy Under GA Vishal Gupta, Renu Wakhloo, Anjali Mehta, Satya Dev Gupta Abstract The aim of the present study was to compare the antiemetic effect of intravenous Granisetron, Ondansetron & Metoclopramide in a randomized blinded study for prophylaxis of post operative nausea and vomiting (PONV) in patients undergoing laparoscopic cholecystectomy under general anaesthesia. 60 patients (ASA I & II) undergoing laparoscopic cholecystectomy under general anaesthesia were randomly allocated into three equal groups (n=20). Emetic episodes in first 24 hours were recorded and compared in different study groups. Results were analyzed. Minimal emetic episodes were observed in early post-operative period (1-12hrs) in patients who had received intravenous granisetron in comparison to ondansetron and metoclopramide. However, after 12 hours emesis free periods were statistically insignificant between group A and B while patients in group C had no antiemetic effect. Keywords Post Operative Nausea and Vomiting (PONV), Granisetron, Ondensetron, Metoclopramide Introduction The most common and distressing symptoms, which vascular anastomoses and increased intracranial follow anaesthesia and surgery, are pain and emesis. The pressure(4). The anaesthetic consequences are aspiration syndrome of nausea, retching and vomiting is known as pneumonitis and discomfort in recovery. For institutions 'sickness' and each part of it can be distinguished as a there is increased financial burden because of increased separate entity (1). PONV (post operative nausea and nursing care, delayed discharge from Phase I and II vomiting) has been characterized as big 'little problem(2) recovery units and unexpected admissions. Hence, and has been a common complication for both in patients prophylactic antiemetic therapy is needed for all these and out patients undergoing virtually all types of surgical patients.
    [Show full text]
  • International Journal of Medicine and Pharmaceutical Research
    Wayal Sunil Anil et al, IJMPR, 2019, 7(6): 180-183 CODEN (USA): IJCPNH | ISSN: 2321-2624 International Journal of Medicine and Pharmaceutical Research Journal Home Page: www.pharmaresearchlibrary.com/ijmpr R E S E A R C H A R T I C L E Formulation and In-vitro Evaluation of Alosetron Oral Thin Films Wayal Sunil Anil1, G.S. Valluri2, Gampa Vijay Kumar3 Department of Pharmacy, KGR Institute of Technology and Management, Rampally, Kesara, Medchal, Telangana, India. A B S T R A C T Alosetron, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome. In present study oral thin films of Alosetron were developed to have a faster on set of action. The oralthin films were developed by using polymers Guar gum, Pullulan and PVP K30.Oral thin films were prepared by employing solvent casting method. Propylene glycol was selected as permeation enhancer and plasticizer. Drug excipient compatibility studies were carried out by using FTIR, and it was observed that there were no interactions. Formulations were prepared with the varying concentrations polymers ranging from F1-F9, and all the formulations were evaluated for various physical parameters Physical appearance, Weight variation, Thickness, Folding endurance, Tensile strength, Drug content, Moisture uptake, Moisture content and all the results were found to be were found to be within the pharmacopeial limits, in-vitro drug release studies by using USP dissolution Apparatus Type II. Among all the 9 formulations F4 formulation which contain Pullulan 10mg and shown 97.06% cumulative drug release within 30 min.
    [Show full text]
  • Comprehensive Pgx Report for 1 / 31 Examples of Different Levels of Evidence for Pgx Snps
    Comprehensive PGx report for PERSONAL DETAILS Advanced Diagnostics Laboratory LLC CLIA:31D2149403 Phone: Fax: PATIENT DOB Address: 1030 North Kings Highway Suite 304 Cherry Hill, NJ 08034 GENDER FEMALE Website: http://advanceddiagnosticslaboratory.com/ SPECIMEN TYPE Oral Fluid LABORATORY INFORMATION ORDERING PHYSICIAN ACCESSION NUMBER 100344 FACILITY COLLECTION DATE 08/10/2020 RECEIVED DATE 08/14/2020 REPORT GENERATED 09/08/2020 LABORATORY DIRECTOR Dr. Jeanine Chiaffarano Current Patient Medication Clonidine (Catapres, Kapvay) The personalized pharmacogenomics profile of this patient reveals intermediate CYP2D6-mediated metabolism, extensive CYP1A2-mediated metabolism, and extensive CYP3A5-mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Losartan (Cozaar) The personalized pharmacogenomics profile of this patient reveals extensive CYP2C9-mediated metabolism, extensive CYP3A4-mediated metabolism, and extensive CYP3A5-mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Diltiazem (Cardizem, Tiazac) The personalized pharmacogenomics profile of this patient reveals extensive CYP3A4-mediated metabolism, intermediate CYP2C19-mediated metabolism, and extensive CYP3A5- mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Labetalol (Normodyne, Trandate) The personalized pharmacogenomics profile of this patient reveals intermediate CYP2D6-mediated metabolism, and intermediate CYP2C19-mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Mycophenolate mofetil (Myfortic, CellCept) The personalized pharmacogenomics profile of this patient reveals extensive CYP3A4-mediated metabolism, extensive CYP3A5-mediated metabolism, and extensive CYP2C8-mediated metabolism.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: the Iceberg Still Lies Beneath the Surface
    1521-0081/71/3/383–412$35.00 https://doi.org/10.1124/pr.118.015487 PHARMACOLOGICAL REVIEWS Pharmacol Rev 71:383–412, July 2019 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: JEFFREY M. WITKIN 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface Gohar Fakhfouri,1 Reza Rahimian,1 Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu Department of Psychiatry and Neuroscience, Faculty of Medicine, CERVO Brain Research Centre, Laval University, Quebec, Quebec, Canada (G.F., R.R.); Sensorion SA, Montpellier, France (J.D.-J.); Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (M.R.Z.); and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (J.-M.B.) Abstract. ....................................................................................384 I. Introduction. ..............................................................................384 II. 5-HT3 Receptor Structure, Distribution, and Ligands.........................................384 A. 5-HT3 Receptor Agonists .................................................................385 B. 5-HT3 Receptor Antagonists. ............................................................385 Downloaded from 1. 5-HT3 Receptor Competitive Antagonists..............................................385 2. 5-HT3 Receptor
    [Show full text]
  • IBS Treatment
    TREATMENTS OF IBS Douglas A. Drossman, MD Co-Director UNC Center for Functional GI & Motility Disorders INTRODUCTION In recent years, there has been increased interest by physicians and the pharmaceutical industry regarding newer treatments for IBS. Before discussing these new treatments, it is important to consider the overall management strategy in IBS. This is necessary because patients with IBS exhibit a wide spectrum of symptoms of varying frequencies and degrees of severity. There is no one ideal treatment for IBS, and the newer medications may work best for only a subset of patients having this disorder. Therefore, the clinician must first apply certain general management approaches and, following this, treatment choices will depend on the nature (i.e., predominant diarrhea, constipation, or bloating, etc.) and severity (mild, moderate, severe) of the symptoms. The symptoms of IBS may have any of several underlying causes. These can include: (a) abnormal motility (uncoordinated or excessive contractions that can lead to diarrhea, constipation, bloating) (b) visceral hypersensitivity (lower pain threshold of the nerves that can produce abdominal discomfort or pain) resulting from the abnormal motility, stress or infection (c) dysfunction of the brain's ability to regulate these visceral (intestinal) activities. Treatments will vary depending on which of these possibilities are occurring. In general, milder symptoms relate primarily to abnormal motility, often in response to food, activity or stress, and/or visceral hypersensitivity. They are commonly treated symptomatically with pharmacological agents directed at the gut. However, more severe symptoms often relate to dysfunction of the brain-gut regulatory system with associated psychosocial effects, and psychological or behavioral treatments and antidepressants are frequently helpful.
    [Show full text]
  • List of Generic Medications
    List of Generic Medications D0001 3,4-methylenedioxy-methamphetamine (MDMA) D0031 Artemisinin D0002 Abacavir D0032 Artesunate D0003 Abiraterone D0033 Asenapine D0004 Acenocoumarol D0034 Aspirin D0005 Aclidinium D0035 Astemizole D0006 Albendazole D0036 Atazanavir D0007 Alfentanyl D0037 Atomoxetine D0008 Alfuzosin D0038 Atorvastatin D0009 Aliskiren D0039 Avanafil D0010 Allopurinol D0040 Axitinib D0011 Almotriptan D0041 Azathioprine D0012 Alogliptin D0042 Azilsartan D0013 Alosetron D0043 Bazedoxifene D0014 Alprazolam D0044 Bedaquiline D0015 Amantadine D0045 Bepridil D0016 Amiodarone D0046 Bicalutamide D0017 Amisulpride D0047 Bisoprolol D0018 Amitriptyline D0048 Boceprevir D0019 Amlodipine D0049 Bosentan D0020 Amobarbital D0050 Bosutinib D0021 Amodiaquine D0051 Brivaracetam D0022 Amoxapine D0052 Bromazepam D0023 Anastrozole D0053 Bromocriptine D0024 Apixaban D0054 Bromperidol D0025 Aprepitant D0055 Brotizolam D0026 Arformoterol D0056 Budesonide D0027 Aripiprazole D0057 Buprenorphine D0028 Armodafinil D0058 Bupropion D0029 Arteether D0059 Buspirone D0030 Artemether D0060 Cabozantinib [email protected] Page 1 List of Generic Medications D0061 Canagliflozin D0091 Clofarabine D0062 Cannabidiol (CBD) D0092 Clofibrate D0063 Cannabinol (CBN) D0093 Clomipramine D0064 Captopril D0094 Clonazepam D0065 Carbamazepine D0095 Clonidine D0066 Carisoprodol D0096 Clopidogrel D0067 Carmustine D0097 Clorazepate D0068 Carvedilol D0098 Clozapine D0069 Celecoxib D0099 Cocaine D0070 Ceritinib D0100 Codeine D0071 Cerivastatin D0101 Colchicine D0072 Cetirizine
    [Show full text]
  • A Four-Country Comparison of Healthcare Systems, Implementation
    Neurogastroenterology & Motility Neurogastroenterol Motil (2014) 26, 1368–1385 doi: 10.1111/nmo.12402 REVIEW ARTICLE A four-country comparison of healthcare systems, implementation of diagnostic criteria, and treatment availability for functional gastrointestinal disorders A report of the Rome Foundation Working Team on cross-cultural, multinational research M. SCHMULSON,* E. CORAZZIARI,† U. C. GHOSHAL,‡ S.-J. MYUNG,§ C. D. GERSON,¶ E. M. M. QUIGLEY,** K.-A. GWEE†† & A. D. SPERBER‡‡ *Laboratorio de Hıgado, Pancreas y Motilidad (HIPAM)-Department of Experimental Medicine, Faculty of Medicine-Universidad Nacional Autonoma de Mexico (UNAM). Hospital General de Mexico, Mexico City, Mexico †Gastroenterologia A, Department of Internal Medicine and Medical Specialties, University La Sapienza, Rome, Italy ‡Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India §Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea ¶Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY, USA **Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA ††Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore ‡‡Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel Key Messages • This report identified seven key issues related to healthcare provision that may impact how patients with FGIDs are investigated, diagnosed and managed. • Variations in healthcare provision around the world in patients with FGIDs have not been reviewed. • We compared four countries that are geographically and culturally diverse, and exhibit differences in the healthcare coverage provided to their population: Italy, South Korea, India and Mexico. • Since there is a paucity of publications relating to the issues covered in this report, some of the findings are based on the authors’ personal perspectives, press reports and other published sources.
    [Show full text]
  • Efficacy of Eluxadoline in Irritable Bowel Syndrome with Diarrhea
    This is a repository copy of Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/156693/ Version: Accepted Version Article: Black, CJ, Houghton, LA and Ford, AC orcid.org/0000-0001-6371-4359 (2020) Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea. American Journal of Gastroenterology, 115 (3). pp. 483-484. ISSN 0002-9270 10.14309/ajg.0000000000000518 © The American College of Gastroenterology 2020. All Rights Reserved. This is an author produced version of correspondence published in The American Journal of Gastroenterology. Uploaded in accordance with the publisher's self-archiving policy. Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Black et al Page 1 of 11 TITLE PAGE Title: Relative Efficacy of Eluxadoline in Irritable Bowel Syndrome. Authors: Christopher J. Black1, 2, Lesley A. Houghton, 2, Alexander C. Ford1, 2. 1Leeds Gastroenterology Institute, St.
    [Show full text]